Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance

por Wu, Zhuo-Xun, Yang, Yuqi, Teng, Qiu-Xu, Wang, Jing-Quan, Lei, Zi-Ning, Wang, Jing-Qiu, Lusvarghi, Sabrina, Ambudkar, Suresh V., Yang, Dong-Hua, Chen, Zhe-Sheng
Publicado 2020